Methylphenidate Retard Viatris (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of the neurotransmitters norepinephrine and dopamine at neuronal synapses. By preventing their removal, the drug raises their levels in the brain, enhancing signaling pathways that regulate attention, alertness, and impulse control. This increased neurotransmitter activity underlies its therapeutic effects.

The appropriate dose of Methylphenidate Retard is individualized and determined by a qualified prescriber based on the patient’s age, condition severity, and response to therapy. Dosage adjustments are made during follow‑up visits to achieve optimal benefit while minimizing side effects.

Safety data for methylphenidate use in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their specific situation with a medical professional before starting or continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methylphenidate Retard. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate belongs to the central nervous system stimulant class and is often compared with amphetamine‑based products such as mixed amphetamine salts. Both increase dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake, whereas amphetamines also promote release. Choice between them depends on individual response, side‑effect profile, and prescriber preference.

Methylphenidate Retard should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat. Keep it out of reach of children and do not use if the packaging is damaged or the tablet appears discolored.

The medication is taken orally, usually as a whole tablet that should be swallowed with water. It is designed for extended release, providing a gradual increase in drug concentration over several hours. Patients should follow the prescriber’s instructions regarding timing, food intake, and whether the tablet can be split or crushed.

Serious risks include cardiovascular events such as hypertension, tachycardia, or chest pain, and psychiatric effects like new or worsening psychosis, mania, or severe anxiety. Rarely, allergic reactions such as rash, swelling, or anaphylaxis may occur. Patients should seek immediate medical attention if they experience any of these symptoms.

Methylphenidate Retard is contraindicated in individuals with known hypersensitivity to methylphenidate or any component of the formulation, those with severe cardiovascular disorders, uncontrolled hypertension, hyperthyroidism, or a history of psychosis. It should also be avoided in patients currently taking monoamine oxidase inhibitors (MAOIs) or other prohibited medications.